• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Statins are 'safe, effective and should be used more widely'
Conclusion This study reviews evidence from randomised controlled trials (RCTs) and observational studies to better evaluate the effects and safety of statin therapy. It provides valuable data on the size of the benefits compared with the risks, informing a topic that has had much media coverage in recent times. The researchers highlight that the benefits of statin therapy for people at risk of cardiovascular disease events far outweigh any possible side effects. But it is still for a doctor and their patient to come to a conclusion about what the best treatment for them may be. If you have been prescribed a statin, it...
Source: NHS News Feed - September 9, 2016 Category: Consumer Health News Tags: QA articles Medication Heart/lungs Source Type: news

New drug shows promise in preventing heart attacks
Conclusion This is a high-quality, well-conducted randomised controlled trial conducted in a very large number of people across multiple countries. To date, it's remained uncertain whether evolocumab reduces the risk of cardiovascular events. This study provides good evidence that the drug reduces the risk of major cardiovascular events in people with high LDL cholesterol levels, and with a high risk of having a cardiovascular event, who are already taking statins. The follow-up is limited to around two years, during which roughly 1 in 10 people experienced a cardiovascular event. The reduction in risk was shown to inc...
Source: NHS News Feed - March 20, 2017 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news

Studies support broader use of cholesterol-lowering statins
The latest guidelines used to determine who should take a cholesterol-lowering statin to prevent heart disease appear to be more accurate and cost-efficient than the previous guidelines. That’s according to two studies led by Harvard researchers, both published in this week’s Journal of the American Medical Association. For many years, the main deciding factor in who needed to take a statin was the level of an individual’s harmful low-density lipoprotein cholesterol (LDL). Updated guidelines published in 2013 by the American College of Cardiology and the American Heart Association moved away from LDL and ...
Source: New Harvard Health Information - July 16, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements cholesterol high cholesterol statins Source Type: news

Statins side effects 'have been overstated,' says study
Conclusion This is a complex study that provides a plausible explanation for the difference in reports of adverse effects of statins in RCTs and observational studies, some of which have suggested as many as 1 in 5 people get side effects from statins. However, we need to be aware of some limitations and unanswered questions: When people knew they were taking statins, they were more likely to report muscle pain than those not taking statins. But they were less likely to report muscle pain than in the first phase of the study, when they didn't know whether they were taking statins or placebo. We don't know why this is. ...
Source: NHS News Feed - May 3, 2017 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news

Statins side effects 'have been overstated', says study
Conclusion This is a complex study that provides a plausible explanation for the difference in reports of adverse effects of statins in RCTs and observational studies, some of which have suggested as many as 1 in 5 people get side effects from statins. However, we need to be aware of some limitations and unanswered questions: When people knew they were taking statins, they were more likely to report muscle pain than those not taking statins. But they were less likely to report muscle pain than in the first phase of the study, when they didn't know whether they were taking statins or placebo. We don't know why this is. ...
Source: NHS News Feed - May 3, 2017 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news

New Studies Give Mixed Results About Taking Fish Oil and Vitamin D
(CHICAGO) — Taking fish oil or vitamin D? Big studies give long-awaited answers on who does and does not benefit from these popular nutrients. Fish oil taken by healthy people, at a dose found in many supplements, showed no clear ability to lower heart or cancer risks. Same for vitamin D. But higher amounts of a purified, prescription fish oil slashed heart problems and heart-related deaths among people with high triglycerides, a type of fat in the blood, and other risks for heart disease. Doctors cheered the results and said they could suggest a new treatment option for hundreds of thousands of patients like these. ...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: MARILYNN MARCHIONE / AP Tags: Uncategorized onetime Supplements Source Type: news

New drug 'effective' for those with intolerable statin side effects
Conclusion The main results of this study relate to the lipid-lowering effects of two alternative non-statin medications. However, it highlights the muscle-related adverse effects that can occur with statins. The study is carefully designed and has many strengths, including: a washout period between drugs to remove any residual effects double-blind design throughout so people didn't know what they were taking sufficient duration for each phase of the study (10 and 24 weeks) to allow effects to develop a good sample size – the researchers calculated beforehand how many people would need to be recruited to ena...
Source: NHS News Feed - April 4, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Older people Source Type: news

This Cholesterol Drug Combination Might Lower Your Risk of Death, Study Finds
(ORLANDO) — A newer cholesterol drug, used with older statin medicines, modestly lowered heart risks and deaths in a big study of heart attack survivors that might persuade insurers to cover the pricey treatment more often. Results on the drug, Praluent, were announced Saturday at an American College of Cardiology conference in Florida. It’s the first time a cholesterol-lowering drug has reduced deaths since statins such as Lipitor and Crestor came out decades ago. “It’s the ultimate outcome; it’s what matters to patients,” said study leader Dr. Philippe Gabriel Steg of Hospital Bichat i...
Source: TIME: Health - March 10, 2018 Category: Consumer Health News Authors: Marilyn Marchione / AP Tags: Uncategorized APH healthytime medicine onetime Source Type: news